SAFETY DATA SHEET

Bezlotoxumab Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Bezlotoxumab Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezlotoxumab</td>
<td>1246264-45-8</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: None known.

Protection of first-aiders: No special precautions are necessary for first aid responders.

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

**Technical measures**

See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation**

Use only with adequate ventilation.

**Advice on safe handling**

Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage

Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid

Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezlotoxumab</td>
<td>1246264-45-8</td>
<td>TWA</td>
<td>2 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type

Particulates type

Hand protection Material

Chemical-resistant gloves

Eye protection

Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES
Bezlotoxumab Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Aqueous solution</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless to pale yellow</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>5.7 - 6.3</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>1.0146 g/cm³</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>No data available</td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, dynamic</td>
<td>1.2 mPa.s (25 °C)</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>1.833 mm²/s (4 °C)</td>
</tr>
<tr>
<td></td>
<td>1.183 mm²/s (25 °C)</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Bezlotoxumab Formulation

Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Bezlotoxumab:
Acute toxicity (other routes of administration) LD50 (Mouse): > 125 mg/kg
Application Route: Intravenous
Remarks: No adverse effect has been observed in acute toxicity tests.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:
Species: Mouse
NOAEL: 50 mg/kg
Application Route: Intravenous
Exposure time: 15 d
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 125 mg/kg
Application Route: Intravenous
Exposure time: 21 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Bezlotoxumab:
Inhalation: Symptoms: Nausea, Headache, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
NOM-002-SCT
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.
Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
SAFETY DATA SHEET

Bezlotoxumab Formulation

Version 1.11
Revision Date: 25.09.2020
SDS Number: 809029-00012
Date of last issue: 16.09.2020
Date of first issue: 22.07.2016

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 25.09.2020

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based on the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8